Amplia Therapeutics Limited Stock Price To Earning
Fundamental analysis of Amplia Therapeutics allows traders to better anticipate movements in Amplia Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Amplia |
Amplia Therapeutics Limited Company Price To Earning Analysis
Amplia Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Amplia Therapeutics Price To Earning | (1.12) X |
Most of Amplia Therapeutics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amplia Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Amplia Therapeutics Limited has a Price To Earning of -1.12 times. This is 104.33% lower than that of the Healthcare sector and 122.72% lower than that of the Biotechnology industry. The price to earning for all United States stocks is 103.9% higher than that of the company.
Amplia Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amplia Therapeutics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Amplia Therapeutics could also be used in its relative valuation, which is a method of valuing Amplia Therapeutics by comparing valuation metrics of similar companies.Amplia Therapeutics is currently under evaluation in price to earning category among its peers.
Amplia Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (1.75) % | |||
| Operating Margin | (1.75) % | |||
| Current Valuation | 4.82 M | |||
| Shares Outstanding | 194.01 M | |||
| Shares Owned By Insiders | 22.09 % | |||
| Shares Owned By Institutions | 23.14 % | |||
| Price To Earning | (1.12) X | |||
| Price To Book | 0.60 X | |||
| Price To Sales | 3.97 X | |||
| Revenue | 2.99 M | |||
| Gross Profit | 1.83 M | |||
| EBITDA | (3.64 M) | |||
| Net Income | (3.64 M) | |||
| Cash And Equivalents | 14.61 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 2.1 M | |||
| Debt To Equity | 0.1 % | |||
| Current Ratio | 31.18 X | |||
| Book Value Per Share | 0.1 X | |||
| Cash Flow From Operations | (4.4 M) | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 25 | |||
| Beta | 0.4 | |||
| Market Capitalization | 12.13 M | |||
| Total Asset | 24.48 M | |||
| Retained Earnings | (113 M) | |||
| Working Capital | 8 M | |||
| Current Asset | 9 M | |||
| Current Liabilities | 1000 K | |||
| Z Score | -2.6 | |||
| Net Asset | 24.48 M |
About Amplia Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amplia Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amplia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amplia Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Other Information on Investing in Amplia Pink Sheet
Amplia Therapeutics financial ratios help investors to determine whether Amplia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amplia with respect to the benefits of owning Amplia Therapeutics security.